ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL1144
CHEMBL1144
Compound Name PRAVASTATIN
ChEMBL Synonyms PRAVASTATIN SODIUM | LIPEMOL | PRAVASTATIN | CS-514 | EPTASTATIN SODIUM | LIPLAT | Pravachol | PRAVACHOL | LIPOSTAT | ELISOR | SQ-31,000
Max Phase 4 (Approved)
Trade Names ELISOR | LIPOSTAT | PRAVACHOL | LIPLAT | PRAVASTATIN SODIUM | LIPEMOL
Molecular Formula C23H36O7

Additional synonyms for CHEMBL1144 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H] ...
Download SMILES
Standard InChI InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14 ...
Download InChI
Standard InChI Key TUZYXOIXSAXUGO-PZAWKZKUSA-N

Sources

  • AstraZeneca Deposited Data
  • British National Formulary
  • Curated Drug Metabolism Pathways
  • DrugMatrix
  • HeCaToS Compounds
  • Orange Book
  • PubChem BioAssays
  • Scientific Literature
  • TP-search Transporter Database
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL1144

Molecule Features

CHEMBL1144 compound icon
Drug Type:Natural Product-derived Rule of Five:Y First In Class:N Chirality:Single Stereoisomer Prodrug:N Oral:Y Parenteral:N Topical:N Black Box:N Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
HMG-CoA reductase inhibitor HMG-CoA reductase DailyMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
LeukemiaD007938EFO:0000565leukemia2ClinicalTrials
ClinicalTrials
Multiple Sclerosis, Relapsing-RemittingD020529EFO:0003929relapsing-remitting multiple sclerosis3ClinicalTrials
Lung NeoplasmsD008175EFO:0001071lung carcinoma3ClinicalTrials
Acute Kidney InjuryD058186HP:0001919Acute kidney injury1ClinicalTrials
FibrosisD005355EFO:0006890fibrosis2ClinicalTrials
Hyperlipoproteinemia Type IIID006952Orphanet:412Hyperlipoproteinemia type 33ClinicalTrials
Polycystic Kidney, Autosomal DominantD016891EFO:1001496Autosomal dominant polycystic kidney disease3ClinicalTrials
HyperlipidemiasD006949EFO:0003774hyperlipidemia3ClinicalTrials
Lupus Erythematosus, SystemicD008180EFO:0002690systemic lupus erythematosus2ClinicalTrials
ProgeriaD011371Orphanet:740Hutchinson-Gilford progeria syndrome2ClinicalTrials
Carcinoma, HepatocellularD006528EFO:0000182hepatocellular carcinoma3ClinicalTrials
ClinicalTrials
HypercholesterolemiaD006937HP:0003124hypercholesterolemia3ClinicalTrials
ClinicalTrials
Diabetes Mellitus, Type 1D003922EFO:0001359type I diabetes mellitus3ClinicalTrials
CarcinomaD002277EFO:0000313carcinoma2ClinicalTrials
Cardiovascular DiseasesD002318EFO:0000319cardiovascular disease4ATC
HIV InfectionsD015658EFO:0000180HIV-1 infection2ClinicalTrials
HIV InfectionsD015658EFO:0000764HIV infection2ClinicalTrials
ClinicalTrials
Mucocutaneous Lymph Node SyndromeD009080EFO:0004246mucocutaneous lymph node syndrome2ClinicalTrials
PneumoniaD011014EFO:0003106pneumonia0ClinicalTrials
Pre-EclampsiaD011225EFO:0000668preeclampsia1ClinicalTrials
Hyperlipidemia, Familial CombinedD006950Orphanet:79211Combined hyperlipidemia3ClinicalTrials
ClinicalTrials
Arthritis, RheumatoidD001172EFO:0000685rheumatoid arthritis1ClinicalTrials
HypertensionD006973EFO:0000537hypertension3ClinicalTrials
Lipid Metabolism DisordersD052439Orphanet:309005Disorder of lipid metabolism2ClinicalTrials
Breast NeoplasmsD001943EFO:0000305breast carcinoma1ClinicalTrials
Coronary Artery DiseaseD003324EFO:0000378coronary artery disease2ClinicalTrials
Myocardial IschemiaD017202EFO:1001375Myocardial Ischemia2ClinicalTrials
Renal Insufficiency, ChronicD051436EFO:0003884chronic kidney disease3ClinicalTrials

Clinical Data

ClinicalTrials.gov PRAVASTATIN
The Cochrane Collaboration PRAVASTATIN

Metabolites for CHEMBL1144

Open in full screen

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL1144. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL402 HMG-CoA reductase Homo sapiens 1.000
CHEMBL3247 HMG-CoA reductase Rattus norvegicus 1.000
CHEMBL1987 Prostanoid FP receptor Homo sapiens 0.999
CHEMBL3251 Nuclear factor NF-kappa-B p105 subunit Homo sapiens 0.978
CHEMBL276 Muscarinic acetylcholine receptor M1 Rattus norvegicus 0.602
CHEMBL1293237 Bloom syndrome protein Homo sapiens 0.583
CHEMBL4349 N-acylsphingosine-amidohydrolase Homo sapiens 0.255



10uM


ChEMBL_ID Target Name Organism Score
CHEMBL402 HMG-CoA reductase Homo sapiens 1.000
CHEMBL3247 HMG-CoA reductase Rattus norvegicus 1.000
CHEMBL1697668 Solute carrier organic anion transporter family member 1B1 Homo sapiens 1.000
CHEMBL1743121 Solute carrier organic anion transporter family member 1B3 Homo sapiens 1.000
CHEMBL1987 Prostanoid FP receptor Homo sapiens 0.999
CHEMBL3482 Beta-galactosidase Bos taurus 0.986
CHEMBL276 Muscarinic acetylcholine receptor M1 Rattus norvegicus 0.850
CHEMBL3251 Nuclear factor NF-kappa-B p105 subunit Homo sapiens 0.756
CHEMBL3985 Voltage-dependent calcium channel alpha2delta subunit Sus scrofa 0.657
CHEMBL2672 Muscarinic acetylcholine receptor M1 Bos taurus 0.414
CHEMBL4573 Metabotropic glutamate receptor 6 Homo sapiens 0.400
CHEMBL1828 DNA polymerase alpha subunit Homo sapiens 0.227

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
424.5 424.2461 2.44 10 124.29 ACID


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
6 4 0 7 4 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
4.31 - 2.21 -.88 0 30 0.4

Structural Alerts

There are 2 structural alerts for CHEMBL1144. To view alerts please click here.

Compound Cross References

ATC C - CARDIOVASCULAR SYSTEM
C10 - LIPID MODIFYING AGENTS
C10A - LIPID MODIFYING AGENTS, PLAIN
C10AA - HMG CoA reductase inhibitors
C10AA03 - pravastatin

ChemSpider ChemSpider:TUZYXOIXSAXUGO-PZAWKZKUSA-N
DailyMed pravastatin sodium
Wikipedia Pravastatin

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL1144



ACToR 81093-37-0
BindingDB 20688
Brenda 11499
ChEBI 63618
DrugBank DB00175
DrugCentral 2239
eMolecules 3716196
EPA CompTox Dashboard DTXSID6023498
FDA SRS KXO2KT9N0G
Guide to Pharmacology 2953
Human Metabolome Database HMDB0005022
IBM Patent System BC81DE5E61181F91195DF7D7DE2DBCCB
KEGG Ligand C01844
LINCS LSM-3347
LipidMaps LMFA05000695
Metabolights MTBLC63618
MolPort MolPort-006-167-482
Nikkaji J139.432K
PharmGKB PA451089
PubChem 54687
PubChem: Thomson Pharma 14758460 14880512
SureChEMBL SCHEMBL1117
ZINC ZINC000003798763

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/TUZYXOIXSAXUGO-PZAWKZKUSA-N spacer
spacer